Paper · 33317455

Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer.

Oshima M and 8 others. BMC Gastroenterol, 2020. Cited by 12 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer. Papers, record 33317455. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33317455

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable pancreatic cancer.; PubMed
Journal: BMC Gastroenterol; PubMed
Year: 2020; PubMed
Publication types: Journal Article; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/33317455/; PubMed
DOI: https://doi.org/10.1186/s12876-020-01566-8; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC7734830/; PubMed
The journal: https://conductscience.org/library/journal-index/100968547; PubMed
Citations, by iCite: 12; iCite
Relative citation ratio, by iCite: 0.54; iCite
Revised in PubMed: 2021-05-14; PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	ORCID iD
1	Oshima M	Minoru	https://orcid.org/0000-0002-9114-7985
2	Okano K	Keiichi
3	Suto H	Hironobu
4	Ando Y	Yasuhisa
5	Kamada H	Hideki
6	Masaki T	Tsutomu
7	Takahashi S	Shigeo
8	Shibata T	Toru
9	Suzuki Y	Yasuyuki

Source PubMed

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Carcinoma, Pancreatic Ductal	Major topic
Pancreatic Neoplasms	Major topic
Humans
Neoadjuvant Therapy
Pancreatectomy
Prognosis
Retrospective Studies

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	27,149,487	Clinical Implication of Inflammation-Based Prognostic Score in Pancreatic Cancer: Glasgow Prognostic Score Is the Most Reliable Parameter.	Medicine (Baltimore)	2016	https://conductscience.org/library/papers/27149487	PubMed
2	28,608,121	A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.	Ann Surg Oncol	2017	https://conductscience.org/library/papers/28608121	PubMed
3	27,243,381	Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma.	Cancer	2016	https://conductscience.org/library/papers/27243381	PubMed
4	26,213,211	Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.	Acta Oncol	2016	https://conductscience.org/library/papers/26213211	PubMed
5	23,470,568	Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.	Ann Surg	2013	https://conductscience.org/library/papers/23470568	PubMed
6	28,602,879	Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: A systematic review and meta-analysis of 66 cohort studies.	Cancer Treat Rev	2017	https://conductscience.org/library/papers/28602879	PubMed
7	22,995,477	The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer.	Cancer Treat Rev	2013	https://conductscience.org/library/papers/22995477	PubMed
8	9,880,770	Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas.	J Hepatobiliary Pancreat Surg	1998	https://conductscience.org/library/papers/9880770	PubMed
9	22,692,586	Impact of sarcopenia on outcomes following resection of pancreatic adenocarcinoma.	J Gastrointest Surg	2012	https://conductscience.org/library/papers/22692586	PubMed
10	16,437,757	Cancer-associated malnutrition.	Eur J Oncol Nurs	2005	https://conductscience.org/library/papers/16437757	PubMed

1 to 10 of 34

See all 34 references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.

PMID	Title	Journal	Year	In Papers	Source
42,298,206	Association between anamorelin therapy and renal function in patients with cancer cachexia: a propensity score-matched retrospective study.	Eur J Clin Pharmacol	2026	https://conductscience.org/library/papers/42298206	PubMed
37,784,000	The Clinical Impact of Change in the C-Reactive Protein/Albumin Ratio in Gastric Cancer Patients Who Receive Curative Treatment.	J Gastrointest Cancer	2024	https://conductscience.org/library/papers/37784000	PubMed
37,509,622	Preoperative C-Reactive Protein-to-Albumin Ratio and Its Ability to Predict Outcomes of Pancreatic Cancer Resection: A Systematic Review.	Biomedicines	2023	https://conductscience.org/library/papers/37509622	PubMed
35,201,490	Predictive factors of operability after neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer: a single-center retrospective study.	Discov Oncol	2022	https://conductscience.org/library/papers/35201490	PubMed
34,758,773	Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma.	BMC Cancer	2021	https://conductscience.org/library/papers/34758773	PubMed

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
ALB	213	PubTator's text mining	https://conductscience.org/library/genes/213	NCBI Gene
CEACAM3	1,084	PubTator's text mining	https://conductscience.org/library/genes/1084	NCBI Gene
CRP	1,401	PubTator's text mining	https://conductscience.org/library/genes/1401	NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33317455

GET https://conductscience.org/api/papers/v1/33317455/references?page=2

API reference For AI assistants